Venture Investment Bank for Early Stage Technology Companies We Invest Through: –Angel &...
-
Upload
alban-edwards -
Category
Documents
-
view
216 -
download
1
Transcript of Venture Investment Bank for Early Stage Technology Companies We Invest Through: –Angel &...
• Venture Investment Bank for Early Stage Technology Companies
• We Invest Through:– Angel & Institutional Investor Members– Capital Managed Internally
• NASD\Broker Dealer
Who We Are
SeedSeed ‘A’ Round ‘B+’ Rounds Mezzanine IPO/Exit‘A’ Round ‘B+’ Rounds Mezzanine IPO/Exit
$200k $.5 – $5M $10M+ $10 - $30M $40M+
Capital ChasmCapital Chasm
Early Stage
5. Do your own Competitive Analysis Research
Ten Highly Effective Habits ofSuccessful Angel Investing
10. Know who you pass the Baton to – before you invest
Ten Highly Effective Habits ofSuccessful Angel Investing
• Initial Screening by Angel Capital Staff
• Qualified Deals go to Expert Angel
Members for Analysis
• Engage VCs in Due Diligence Review
• Engage Relevant Strategic Investors
Deal Selection Process
• Angel Investors with Deep Relevant Industry Experience Willing to:
– Invest
– Serve as Advisors
• VCs Willing to Fund Later Rounds Based on Certain Milestones
• Defensible IP
Deal Selection Criteria
• Introduce:– Expert Angels Who Invest and Join Board– Industry Board Members– Strategic Relationships– VCs with Relevant Expertise
• Valuation and Deal Structure
• Ongoing Corporate Finance Services
Deal Support
• Disruptive Technology in Intelligent Storage Networks
• 12 patents filed, more to come• Market projected to grow 900% by 2003 to $6.7B• Experienced management team has built two
successful companies• Elite industry board• Key industry relationships in place
BioRight International, Inc.
Breakthrough Nonprescription Cold& Allergy Medicines
•Launched 11/00 - Sales Exceeding $1.3 Million•Distribution in Over 22,000 Retail Pharmacies – Walgreens, Rite-Aid, Eckerds, Safeway, Osco, Longs•Pipeline for New Product Introductions•Revenue Growth to Over $100 Million Within 5 Years•Management Combines Medical Expertise With 25 Year Track Record of Retail Product Introductions
• Multifocal Contact Lens With Strong Patents and High Consumer Demand
• Clinical Data Consistently Outperforms Any Lens on the Market (Including J&J Acuvue)
• FDA Approval Received for:– Custom (Lathed Lens) Launched in US and Canada
– Cast Molded Lens (Disposable & Mass Produced)
• CE Mark Received for Astigmatic Intraocular Lens